About Serum response factor-binding protein 1
Serum response factor-binding protein 1 (SRFBP1) is a protein
from Homo sapiens identified by UniProt accession
Q8NEF9, 429 residues long.
MolForge cross-references it against 0 known binders and
25 disease associations.
Target properties
| Protein name | Serum response factor-binding protein 1 |
| UniProt accession | Q8NEF9 |
| Gene | SRFBP1 |
| Organism | Homo sapiens |
| Length | 429 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (25)
Diseases linked to this target (Open Targets).
- body height · score 0.33
- FEV/FVC ratio · score 0.30
- BMI-adjusted waist circumference · score 0.27
- coronary artery disease · score 0.27
- pulse pressure measurement · score 0.26
- Inguinal hernia · score 0.15
- Hernia · score 0.12
- Anti-Toxoplasma gondii IgG measurement · score 0.09
- Young adult-onset Parkinsonism · score 0.07
- vital capacity · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8NEF9-F1 | alphafold | PREDICTED | 61.92 | — |
Amino-acid sequence (429 residues)
MAQPGTLNLN NEVVKMRKEV KRIRVLVIRK LVRSVGRLKS KKGTEDALLK NQRRAQRLLE EIHAMKELKP DIVTKSALGD DINFEKIFKK PDSTATERAI ARLAVHPLLK KKIDVLKAAV QAFKEARQNV AEVESSKNAS EDNHSENTLY SNDNGSNLQR EATVISEQKV KETKILAKKP IHNSKEKIAK MEHGPKAVTI ANSPSKPSEK DSVVSLESQK TPADPKLKTL SQTKKNKGSD SSLSGNSDGG EEFCEEEKEY FDDSTEERFY KQSSMSEDSD SGDDFFIGKV RRTRKKESSC HSSVKEQKPL EKVFLKEDTG ETHGDTRNDK IKPSTETRKL ESVFFHSLSG SKSSRRNFKE QAPKTRSLDF PQNEPQIKNQ FNKKLSGRLE NTKQQLQLPL HPSWEASRRR KEQQSNIAVF QGKKITFDD
Explore Serum response factor-binding protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets